Global Hyperpigmentation Treatment

Hyperpigmentation Treatment Comprehensive Study by Disease Type (Melasma, Solar lentigines, Melanoma, Precursors, Vitiligo), Distribution Channel (Beauty Stores, Drug Stores, Dermatology Clinics, Aesthetic Clinics, Others), Treatment Type (Retinols, Chemical Peel, Prescription Medications, Laser Therapies, Ablative, Non-Ablative, Others) Players and Region - Global Market Outlook to 2028

Hyperpigmentation Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Hyperpigmentation Treatment Market Scope
Hyperpigmentation is a medical term used to describe darker patches of skin from excess melanin production. This can be caused by acne scars and sun damage to hormone fluctuations. Hyperpigmentation is characterized by the age spots, brown spots, freckles, melasma and post-inflammatory hyperpigmentation. Skin darkening occurs as a result of melanin augmentation beneath the epidermis layer of the skin. Some medications and certain health conditions can also lead to hyperpigmentation. It can be cured by various methods or treatments which includes avoiding sun exposure and using removal techniques such as cosmetic treatments (laser therapy, intense pulsed light and chemical peels), creams, and home remedies. Laser treatment and light therapies have become a popular therapy choice which drives the growth of hyperpigmentation treatment market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledEpisciences (United States), Vivier Pharma (India), La Roche-Posay (Japan), Pierre Fabre Dermo Cosmetique (France), Bayer (Germany), Alvogen (New York), Allergen (Ireland), Obagi Medical Products (United States), SkinCeuticals International (United States) and L'Oréal Paris (France)
CAGR%


Hyperpigmentation Treatment Market is a fragmented market due to the presence of various players. The players are focusing on developing and originating innovative treatments for hyperpigmentation. The companies are also planning strategic activities such as product launch, collaborations, mergers and acquisitions to sustain in the market and maintain their competitive edge.

Episciences (United States), Vivier Pharma (India), La Roche-Posay (Japan), Pierre Fabre Dermo Cosmetique (France), Bayer (Germany), Alvogen (New York), Allergen (Ireland), Obagi Medical Products (United States), SkinCeuticals International (United States) and L'Oréal Paris (France) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Hyperpigmentation Treatment market by Type and Region with country level break-up.

On the basis of geography, the market of Hyperpigmentation Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
On March 2023, the local arm of the world’s largest cosmetics company, L’Oréal, is scouting for acquisitions in the skin and make-up market in India, said a top company executive, adding that it seeks to capitalize on the country’s rising demand for beauty products.
On October 2021, Immunoprecise Antibodies Ltd. and the Pierre Fabre pharmaceutical group announced that IPA’s subsidiary, Talem Therapeutics LLC (“Talem”), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem’s portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biotechnology sector.


Market Growth Drivers:
Customer Demand for Skin Brightening Products., Changing Lifestyles Boost the Market Growth., Some Subscription Options May Make Products More Affordable. and Laser Treatment and Light Therapy.

Challenges:
Side Effects Of Laser Treatment May Negatively Influence The Market.

Restraints:
High Cost of Treatment. and Low Healthcare Budgets in Developing Countries.

Opportunities:
Rise In The Research And Development Activities And Emerging Markets.

Report Objectives / Segmentation Covered

By Disease Type
  • Melasma
  • Solar lentigines
  • Melanoma
  • Precursors
  • Vitiligo

By Distribution Channel
  • Beauty Stores
  • Drug Stores
  • Dermatology Clinics
  • Aesthetic Clinics
  • Others

By Treatment Type
  • Retinols
  • Chemical Peel
  • Prescription Medications
  • Laser Therapies
  • Ablative
  • Non-Ablative
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Customer Demand for Skin Brightening Products.
      • 3.2.2. Changing Lifestyles Boost the Market Growth.
      • 3.2.3. Some Subscription Options May Make Products More Affordable.
      • 3.2.4. Laser Treatment and Light Therapy.
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Of Laser Treatment May Negatively Influence The Market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hyperpigmentation Treatment, by Disease Type, Distribution Channel, Treatment Type and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Hyperpigmentation Treatment (Value)
      • 5.2.1. Global Hyperpigmentation Treatment by: Disease Type (Value)
        • 5.2.1.1. Melasma
        • 5.2.1.2. Solar lentigines
        • 5.2.1.3. Melanoma
        • 5.2.1.4. Precursors
        • 5.2.1.5. Vitiligo
      • 5.2.2. Global Hyperpigmentation Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Beauty Stores
        • 5.2.2.2. Drug Stores
        • 5.2.2.3. Dermatology Clinics
        • 5.2.2.4. Aesthetic Clinics
        • 5.2.2.5. Others
      • 5.2.3. Global Hyperpigmentation Treatment by: Treatment Type (Value)
        • 5.2.3.1. Retinols
        • 5.2.3.2. Chemical Peel
        • 5.2.3.3. Prescription Medications
        • 5.2.3.4. Laser Therapies
        • 5.2.3.5. Ablative
        • 5.2.3.6. Non-Ablative
        • 5.2.3.7. Others
      • 5.2.4. Global Hyperpigmentation Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Hyperpigmentation Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Episciences (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Vivier Pharma (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. La Roche-Posay (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pierre Fabre Dermo Cosmetique (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alvogen (New York)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergen (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Obagi Medical Products (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. SkinCeuticals International (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. L'Oréal Paris (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hyperpigmentation Treatment Sale, by Disease Type, Distribution Channel, Treatment Type and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Hyperpigmentation Treatment (Value)
      • 7.2.1. Global Hyperpigmentation Treatment by: Disease Type (Value)
        • 7.2.1.1. Melasma
        • 7.2.1.2. Solar lentigines
        • 7.2.1.3. Melanoma
        • 7.2.1.4. Precursors
        • 7.2.1.5. Vitiligo
      • 7.2.2. Global Hyperpigmentation Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Beauty Stores
        • 7.2.2.2. Drug Stores
        • 7.2.2.3. Dermatology Clinics
        • 7.2.2.4. Aesthetic Clinics
        • 7.2.2.5. Others
      • 7.2.3. Global Hyperpigmentation Treatment by: Treatment Type (Value)
        • 7.2.3.1. Retinols
        • 7.2.3.2. Chemical Peel
        • 7.2.3.3. Prescription Medications
        • 7.2.3.4. Laser Therapies
        • 7.2.3.5. Ablative
        • 7.2.3.6. Non-Ablative
        • 7.2.3.7. Others
      • 7.2.4. Global Hyperpigmentation Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hyperpigmentation Treatment: by Disease Type(USD Million)
  • Table 2. Hyperpigmentation Treatment Melasma , by Region USD Million (2017-2022)
  • Table 3. Hyperpigmentation Treatment Solar lentigines , by Region USD Million (2017-2022)
  • Table 4. Hyperpigmentation Treatment Melanoma , by Region USD Million (2017-2022)
  • Table 5. Hyperpigmentation Treatment Precursors , by Region USD Million (2017-2022)
  • Table 6. Hyperpigmentation Treatment Vitiligo , by Region USD Million (2017-2022)
  • Table 7. Hyperpigmentation Treatment: by Distribution Channel(USD Million)
  • Table 8. Hyperpigmentation Treatment Beauty Stores , by Region USD Million (2017-2022)
  • Table 9. Hyperpigmentation Treatment Drug Stores , by Region USD Million (2017-2022)
  • Table 10. Hyperpigmentation Treatment Dermatology Clinics , by Region USD Million (2017-2022)
  • Table 11. Hyperpigmentation Treatment Aesthetic Clinics , by Region USD Million (2017-2022)
  • Table 12. Hyperpigmentation Treatment Others , by Region USD Million (2017-2022)
  • Table 13. Hyperpigmentation Treatment: by Treatment Type(USD Million)
  • Table 14. Hyperpigmentation Treatment Retinols , by Region USD Million (2017-2022)
  • Table 15. Hyperpigmentation Treatment Chemical Peel , by Region USD Million (2017-2022)
  • Table 16. Hyperpigmentation Treatment Prescription Medications , by Region USD Million (2017-2022)
  • Table 17. Hyperpigmentation Treatment Laser Therapies , by Region USD Million (2017-2022)
  • Table 18. Hyperpigmentation Treatment Ablative , by Region USD Million (2017-2022)
  • Table 19. Hyperpigmentation Treatment Non-Ablative , by Region USD Million (2017-2022)
  • Table 20. Hyperpigmentation Treatment Others , by Region USD Million (2017-2022)
  • Table 21. South America Hyperpigmentation Treatment, by Country USD Million (2017-2022)
  • Table 22. South America Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 23. South America Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 24. South America Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 25. Brazil Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 26. Brazil Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 27. Brazil Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 28. Argentina Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 29. Argentina Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 30. Argentina Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 31. Rest of South America Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 32. Rest of South America Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 34. Asia Pacific Hyperpigmentation Treatment, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 36. Asia Pacific Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 37. Asia Pacific Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 38. China Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 39. China Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 40. China Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 41. Japan Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 42. Japan Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 43. Japan Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 44. India Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 45. India Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 46. India Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 47. South Korea Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 48. South Korea Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 49. South Korea Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 50. Taiwan Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 51. Taiwan Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 52. Taiwan Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 53. Australia Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 54. Australia Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 55. Australia Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 58. Rest of Asia-Pacific Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 59. Europe Hyperpigmentation Treatment, by Country USD Million (2017-2022)
  • Table 60. Europe Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 61. Europe Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 62. Europe Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 63. Germany Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 64. Germany Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 65. Germany Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 66. France Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 67. France Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 68. France Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 69. Italy Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 70. Italy Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 71. Italy Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 72. United Kingdom Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 73. United Kingdom Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 74. United Kingdom Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 75. Netherlands Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 76. Netherlands Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 77. Netherlands Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 78. Rest of Europe Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 79. Rest of Europe Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 80. Rest of Europe Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 81. MEA Hyperpigmentation Treatment, by Country USD Million (2017-2022)
  • Table 82. MEA Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 83. MEA Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 84. MEA Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 85. Middle East Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 86. Middle East Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 87. Middle East Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 88. Africa Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 89. Africa Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 90. Africa Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 91. North America Hyperpigmentation Treatment, by Country USD Million (2017-2022)
  • Table 92. North America Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 93. North America Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 94. North America Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 95. United States Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 96. United States Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 97. United States Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 98. Canada Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 99. Canada Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 100. Canada Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 101. Mexico Hyperpigmentation Treatment, by Disease Type USD Million (2017-2022)
  • Table 102. Mexico Hyperpigmentation Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 103. Mexico Hyperpigmentation Treatment, by Treatment Type USD Million (2017-2022)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Hyperpigmentation Treatment: by Disease Type(USD Million)
  • Table 115. Hyperpigmentation Treatment Melasma , by Region USD Million (2023-2028)
  • Table 116. Hyperpigmentation Treatment Solar lentigines , by Region USD Million (2023-2028)
  • Table 117. Hyperpigmentation Treatment Melanoma , by Region USD Million (2023-2028)
  • Table 118. Hyperpigmentation Treatment Precursors , by Region USD Million (2023-2028)
  • Table 119. Hyperpigmentation Treatment Vitiligo , by Region USD Million (2023-2028)
  • Table 120. Hyperpigmentation Treatment: by Distribution Channel(USD Million)
  • Table 121. Hyperpigmentation Treatment Beauty Stores , by Region USD Million (2023-2028)
  • Table 122. Hyperpigmentation Treatment Drug Stores , by Region USD Million (2023-2028)
  • Table 123. Hyperpigmentation Treatment Dermatology Clinics , by Region USD Million (2023-2028)
  • Table 124. Hyperpigmentation Treatment Aesthetic Clinics , by Region USD Million (2023-2028)
  • Table 125. Hyperpigmentation Treatment Others , by Region USD Million (2023-2028)
  • Table 126. Hyperpigmentation Treatment: by Treatment Type(USD Million)
  • Table 127. Hyperpigmentation Treatment Retinols , by Region USD Million (2023-2028)
  • Table 128. Hyperpigmentation Treatment Chemical Peel , by Region USD Million (2023-2028)
  • Table 129. Hyperpigmentation Treatment Prescription Medications , by Region USD Million (2023-2028)
  • Table 130. Hyperpigmentation Treatment Laser Therapies , by Region USD Million (2023-2028)
  • Table 131. Hyperpigmentation Treatment Ablative , by Region USD Million (2023-2028)
  • Table 132. Hyperpigmentation Treatment Non-Ablative , by Region USD Million (2023-2028)
  • Table 133. Hyperpigmentation Treatment Others , by Region USD Million (2023-2028)
  • Table 134. South America Hyperpigmentation Treatment, by Country USD Million (2023-2028)
  • Table 135. South America Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 136. South America Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 137. South America Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 138. Brazil Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 139. Brazil Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 140. Brazil Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 141. Argentina Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 142. Argentina Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 143. Argentina Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 144. Rest of South America Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 145. Rest of South America Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 146. Rest of South America Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 147. Asia Pacific Hyperpigmentation Treatment, by Country USD Million (2023-2028)
  • Table 148. Asia Pacific Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 149. Asia Pacific Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 150. Asia Pacific Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 151. China Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 152. China Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 153. China Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 154. Japan Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 155. Japan Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 156. Japan Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 157. India Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 158. India Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 159. India Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 160. South Korea Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 161. South Korea Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 162. South Korea Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 163. Taiwan Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 164. Taiwan Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 165. Taiwan Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 166. Australia Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 167. Australia Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 168. Australia Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 169. Rest of Asia-Pacific Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 170. Rest of Asia-Pacific Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 171. Rest of Asia-Pacific Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 172. Europe Hyperpigmentation Treatment, by Country USD Million (2023-2028)
  • Table 173. Europe Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 174. Europe Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 175. Europe Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 176. Germany Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 177. Germany Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 178. Germany Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 179. France Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 180. France Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 181. France Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 182. Italy Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 183. Italy Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 184. Italy Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 185. United Kingdom Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 186. United Kingdom Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 187. United Kingdom Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 188. Netherlands Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 189. Netherlands Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 190. Netherlands Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 191. Rest of Europe Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 192. Rest of Europe Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 193. Rest of Europe Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 194. MEA Hyperpigmentation Treatment, by Country USD Million (2023-2028)
  • Table 195. MEA Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 196. MEA Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 197. MEA Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 198. Middle East Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 199. Middle East Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 200. Middle East Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 201. Africa Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 202. Africa Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 203. Africa Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 204. North America Hyperpigmentation Treatment, by Country USD Million (2023-2028)
  • Table 205. North America Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 206. North America Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 207. North America Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 208. United States Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 209. United States Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 210. United States Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 211. Canada Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 212. Canada Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 213. Canada Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 214. Mexico Hyperpigmentation Treatment, by Disease Type USD Million (2023-2028)
  • Table 215. Mexico Hyperpigmentation Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 216. Mexico Hyperpigmentation Treatment, by Treatment Type USD Million (2023-2028)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hyperpigmentation Treatment: by Disease Type USD Million (2017-2022)
  • Figure 5. Global Hyperpigmentation Treatment: by Distribution Channel USD Million (2017-2022)
  • Figure 6. Global Hyperpigmentation Treatment: by Treatment Type USD Million (2017-2022)
  • Figure 7. South America Hyperpigmentation Treatment Share (%), by Country
  • Figure 8. Asia Pacific Hyperpigmentation Treatment Share (%), by Country
  • Figure 9. Europe Hyperpigmentation Treatment Share (%), by Country
  • Figure 10. MEA Hyperpigmentation Treatment Share (%), by Country
  • Figure 11. North America Hyperpigmentation Treatment Share (%), by Country
  • Figure 12. Global Hyperpigmentation Treatment share by Players 2022 (%)
  • Figure 13. Global Hyperpigmentation Treatment share by Players (Top 3) 2022(%)
  • Figure 14. Global Hyperpigmentation Treatment share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Episciences (United States) Revenue, Net Income and Gross profit
  • Figure 17. Episciences (United States) Revenue: by Geography 2022
  • Figure 18. Vivier Pharma (India) Revenue, Net Income and Gross profit
  • Figure 19. Vivier Pharma (India) Revenue: by Geography 2022
  • Figure 20. La Roche-Posay (Japan) Revenue, Net Income and Gross profit
  • Figure 21. La Roche-Posay (Japan) Revenue: by Geography 2022
  • Figure 22. Pierre Fabre Dermo Cosmetique (France) Revenue, Net Income and Gross profit
  • Figure 23. Pierre Fabre Dermo Cosmetique (France) Revenue: by Geography 2022
  • Figure 24. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer (Germany) Revenue: by Geography 2022
  • Figure 26. Alvogen (New York) Revenue, Net Income and Gross profit
  • Figure 27. Alvogen (New York) Revenue: by Geography 2022
  • Figure 28. Allergen (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Allergen (Ireland) Revenue: by Geography 2022
  • Figure 30. Obagi Medical Products (United States) Revenue, Net Income and Gross profit
  • Figure 31. Obagi Medical Products (United States) Revenue: by Geography 2022
  • Figure 32. SkinCeuticals International (United States) Revenue, Net Income and Gross profit
  • Figure 33. SkinCeuticals International (United States) Revenue: by Geography 2022
  • Figure 34. L'Oréal Paris (France) Revenue, Net Income and Gross profit
  • Figure 35. L'Oréal Paris (France) Revenue: by Geography 2022
  • Figure 36. Global Hyperpigmentation Treatment: by Disease Type USD Million (2023-2028)
  • Figure 37. Global Hyperpigmentation Treatment: by Distribution Channel USD Million (2023-2028)
  • Figure 38. Global Hyperpigmentation Treatment: by Treatment Type USD Million (2023-2028)
  • Figure 39. South America Hyperpigmentation Treatment Share (%), by Country
  • Figure 40. Asia Pacific Hyperpigmentation Treatment Share (%), by Country
  • Figure 41. Europe Hyperpigmentation Treatment Share (%), by Country
  • Figure 42. MEA Hyperpigmentation Treatment Share (%), by Country
  • Figure 43. North America Hyperpigmentation Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Episciences (United States)
  • Vivier Pharma (India)
  • La Roche-Posay (Japan)
  • Pierre Fabre Dermo Cosmetique (France)
  • Bayer (Germany)
  • Alvogen (New York)
  • Allergen (Ireland)
  • Obagi Medical Products (United States)
  • SkinCeuticals International (United States)
  • L'Oréal Paris (France)
Select User Access Type

Key Highlights of Report


Mar 2023 204 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hyperpigmentation Treatment Quantitative research analysis
Global Hyperpigmentation Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Hyperpigmentation Treatment Market are by end use application [].
The Hyperpigmentation Treatment Market is gaining popularity and expected to see strong valuation by 2028.
  • Customer Demand for Skin Brightening Products.
  • Changing Lifestyles Boost the Market Growth.
  • Some Subscription Options May Make Products More Affordable.
  • Laser Treatment and Light Therapy.

Know More About Global Hyperpigmentation Treatment Report?

Have a Query? Click Here

Other Related Reports

Digital Diabetes Management Comprehensive Study by Type (Devices, Digital Diabetes Apps, Data Management Software and Platforms), Device Type (Wearable Devices, Handheld Devices), End User (Self/Hom...
$ 3450
Perphenazine Comprehensive Study by Application (Psychosis, Antiemetic), Form (Oral, Injectable Solution), Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy, Other), End-Users...
$ 3350
Fluorouracil (5FU) Comprehensive Study by Type (Injection Product, Tablets Product, Oral Solution Product), Application (Breast Cancer, Head and Neck Cancers, Anal Cancer, Stomach Cancer, Colon Cance...
$ 3450
Chagas Disease Treatment Comprehensive Study by Type (Acute Chagas Disease, Chronic Chagas Disease), Application (Hospitals, Homecare, Specialty Clinics, Others), Drugs (Benznidazole, Nifurtimox), Tr...
$ 3750
Conjunctivitis Drugs Comprehensive Study by Type (Antibiotics, Mast Cell Stabilizers, Steroids, Others), Application (Hospitals, Self-Administered), Route of Administration (Topical, Oral, Intra-Vitr...
$ 3450
Cyclobenzaprine Drug Comprehensive Study by Type (Tablet, Capsule), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), End-user (Hospitals, Clinics, Others) Players and Re...
$ 3500